About US
Contact us
-
Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supplyAmong the drugmakers seeking an answer for COVID-19, Regeneron once showed promise in its quest to repurpose an older therapy as a treatment and develop a novel antibody cocktail, too. Now, thanks to2020/7/3
-
J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facilityJohnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 million order from a Maryland CDMO, J&J ann2020/7/2
-
CureVac scores $85M loan to scale COVID-19 shot manufacturing at German siteGerman vaccine maker CureVac recently raised eyebrows for its reported work with electric car maker Tesla to produce mobile mRNA printers to help scale production of a COVID-19 shot. Now, the company2020/7/2
-
Sanofi, Regeneron shut down Kevzara trial in COVID-19 after finding no benefit for ventilated patientsIn the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs, a p2020/7/1
-
J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with EmergentJohnson & Johnson, like all drugmakers in the COVID-19 vaccine race, is hoping to cobble together enough manufacturing capacity to rapidly scale production of its shot hopeful. Now, to the tune o2020/7/1
-
Gilead to start testing inhaled remdesivir, eyeing earlier COVID-19 useGilead Sciences’ infused antiviral remdesivir currently holds an FDA emergency use authorization to treat severe hospitalized COVID-19 patients. But the company is hoping a new formulation could get2020/6/24
-
FDA could approve 'at least one' COVID-19 vaccine before election: analystWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect drug pricing and how drugmakers operate. About sixmonth2020/6/24
-
It's the end of road for hydroxychloroquine in COVID-19 as Novartis, NIH and WHO pull out of trialsThe road for hydroxychloroquine against COVID-19 is coming to an end. Three major clinical programs have been terminated after a U.K. trial found “no clinical benefit” for the malaria drug championed2020/6/23
-
Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggestsPfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag still seems too much for many heart patients2020/6/23
-
GlaxoSmithKline recalls children's Robitussin, Dimetapp with faulty dosing cupsBritish drugmaker GlaxoSmithKline was one of many companies forced to pull its version of heartburn med Zantac off shelves last year after a widespread carcinogen scare. Now, GSK is in hot water for2020/6/22